Samil Pharmaceutical Co.,Ltd reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was KRW 1,112.35 million compared to KRW 1,014.73 million a year ago. Net loss was KRW 1,742.53 million compared to net income of KRW 707.42 million a year ago.

Basic loss per share from continuing operations was KRW 118 compared to basic earnings per share from continuing operations of KRW 55 a year ago. Basic loss per share was KRW 118 compared to basic earnings per share of KRW 55 a year ago.